CatalystPit
TerminalPit ConsensusInsidersPoliticiansInstitutionsNewsScreener

TSHATaysha Gene Therapies, Inc.

NASDAQ · Biological Products, (No Diagnostic Substances)
Last close $4.87 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryBiological Products, (No Diagnostic Substances)
Market cap$1.59B
RECENT INSIDER TRADES
  • 2026-07-10 · Nagendran Sukumar (President and Head of R&D) · SELL
  • 2026-04-13 · Nagendran Sukumar (President and Head of R&D) · SELL
  • 2026-04-13 · Nagendran Sukumar (President and Head of R&D) · OTHER
  • 2026-02-06 · Alam Kamran (CHIEF FINANCIAL OFFICER) · SELL
  • 2026-01-27 · Alam Kamran (CHIEF FINANCIAL OFFICER) · SELL
INSTITUTIONAL OWNERSHIP
Institutional holders221
Shares held331,541,395
Value$2.17B
Percent of shares outstanding101.75%
As of quarter end2026-06-30
RECENT NEWS
  • Taysha Gene Therapies grants RSUs and options to four new employees
  • Taysha Gene Therapies presents TSHA-102 data at Child Neurology Society meeting
CatalystPit
FeaturesComing soonPricingComing soonPrivacyTermsDisclaimerAffiliate TermsContact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS